Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7272590 | 0.95 | ACHE (0.51) | ACHE | |
| Fumaric Acid SCHEMBL29868451 | 0.94 | ACHE (0.48) | ACHE | |
| SCHEMBL7271942 | 0.91 | ACHE (0.49) | ACHE | |
| SCHEMBL7274227 | 0.91 | ACHE (0.52) | ACHE | |
| SCHEMBL7272662 | 0.90 | ACHE (0.49) | ACHE | |
| SCHEMBL7274846 | 0.88 | ACHE (0.56) | ACHE | |
| SCHEMBL7200250 | 0.88 | ABCC1 (0.46) | — | |
| SCHEMBL7281953 | 0.87 | ACHE (0.57) | ACHE | |
| SCHEMBL7274924 | 0.87 | ACHE (0.57) | ACHE | |
| SCHEMBL7283958 | 0.86 | ACHE (0.47) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | claimed |
| EP-2586436-A1 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2013-05-01 | — | — | EP | claimed |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | claimed |
| WO-2009039461-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| US-20090082342-A1 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | claimed |
| US-20090036487-A1 | Combinations | PFIZER INC. | 2009-02-05 | — | — | US | claimed |
| EP-1667722-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | Pfizer Limited (GB) | 2006-06-14 | — | — | EP | claimed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | claimed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | claimed |
| US-10765670-B2 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-09-08 | — | — | US | disclosed |
| EP-2773337-B1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-20180177773-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| EP-2200610-B1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARM INC (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-0481429-B1 | Quinoline derivatives | SS PHARMACEUTICAL CO (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-0987262-A1 | Quinoline derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 2000-03-22 | — | — | EP | disclosed |
| US-5300517-A | Treating Alzheimer's | SS PHARMACEUTICAL CO., LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| US-5240934-A | Cognition activators | SS PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5190951-A | Inhibitors of acetylcholinesterase, treatment of senile dementia | SS PHARMACEUTICAL CO., LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| EP-0481429-A2 | Quinoline derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | ACHE 2/4885 |
| US-20090082342-A1 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | HTR3A, HTR5A, HTR1A | ACHE 670/4885 |
| US-20090036487-A1 | Combinations | CHRNE, CHRND, CHRNG | ACHE 7/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885 |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | ACHE 2/4885 |
| US-20050065176-A1 | Combinations | CHRNE, CHRND, CHRNG | ACHE 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.